CDTX Cidara Therapeutics Inc
8,408
$0.759
$0.021
(2.69%)
| Watchers | 8,408 |
| 52-Wk Low | $0.4601 |
| 52-Wk High | $2.10 |
| Market Cap | $68.64M |
| Volume (M) | 310,610.00 |
| 52-Wk High | $2.10 |
| 52-Wk Low | $0.4601 |
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in ChinaGlobe Newswire • about 23 hours ago
Top-line data expected in Q2 2024 SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the...
Share to Feed
Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first timeSAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company...
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Cidara Therapeutics, Inc. (NASDAQ:CDTX Free Report) Research analysts at HC Wainwright boosted their FY2023 earnings per share estimates for shares of Cidara Therapeutics in a...
Cidara Therapeutics (NASDAQ:CDTX Get Free Report) was downgraded by analysts at StockNews.com from a buy rating to a hold rating in a research note issued to...
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...
Legacy Wealth Asset Management LLC bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX Free Report) in the 2nd quarter, HoldingsChannel reports. The fund bought 30,000...
Revenue Totals $12.7 Million, Cash and Cash Equivalents Reach $48.7 MillionRelated Stocks: CDTX...
Cidara Therapeutics, Inc. (NASDAQ:CDTX Get Free Report) saw a significant decrease in short interest in October. As of October 15th, there was short interest totalling 1,320,000 shares, a...
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Latest CDTX News
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
Globe Newswire • about 23 hours ago
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
Globe Newswire • 7 days ago
Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
Globe Newswire • 17 days ago